Collection of nasal/nasopharyngeal/throat swabs and blood samples from patients presenting at their designated care facility displaying symptoms of COVID-19 and undergoing a SOC SARS-CoV-2 test or those who have tested positive in the past to aid development, calibration and performance evaluation for the LumiraDx POC test.
CAPTURE is a two-stage sample collection study to complete the development, calibration and
performance evaluation phases of the LumiraDx Point of Care (POC) device for the detection of
the SARS-CoV-2 virus and the SARS-CoV-2 IgG/IgM status of infected patients. The study is
split into two arms targeting separate populations throughout each stage.
Stage 1: Consists of sample collection only, to facilitate the in-house development and
calibration of the LumiraDx SARS-CoV-2 assays.
Stage 2: Consists of sample collection to facilitate the performance evaluation of the
LumiraDx SARS-CoV-2 studies. In this stage the testing will be completed onsite using the
LumiraDx POC device.
Diagnostic Test: Sample Collection/Performance Evaluation (A)
This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.
Sample types include:
Nasal/Throat/Nasal Throat Combo/ Nasopharyngeal (as per sites SOC) Swab
Whole Venous Blood
Diagnostic Test: Sample Collection/Performance Evaluation (B)
This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.
Sample types include:
Whole Venous Blood
Fingerstick Capillary Sample
Inclusion Criteria:
1. Patient is at least 18 years of age.
2. Patient meets either of the below categories:
1. Patient is presenting with symptoms indicative of COVID-19 and will be completing
SOC sampling for SARS-CoV-2 PCR testing. (Eligible for Arm A)
2. Patient has had a confirmed positive SARS-CoV-2 PCR test result in the past.
(Eligible for Arm B)
Exclusion Criteria:
1. The patient does not have the capacity to consent as determined by the Research Team
(and the impartial witness if applicable).
2. The patient is deemed to be unsuitable for research at the research teams' discretion.
Barts Health NHS Trust
London, United Kingdom
Homerton University Hospital NHS Foundation Trust
London, United Kingdom
University College London Hospitals NHS Foundation Trust
London, United Kingdom
Samer Elkhodair, Principal Investigator
University College London Hospitals